-
Economic Impact of Blister-Packaging on Medication Adherence in First-Line Multiple Myeloma Treatment
Mar 10, 2025, 14:00 PM -
Trends in Attainment of the Kidney Health Evaluation for Patients With Diabetes Measure Among Insured Individuals in the US, 2021-2024
Mar 10, 2025, 14:00 PM -
Development and Psychometric Validation of Patient-Reported Outcome Measures for Masseter Muscle Prominence (MMP): The Lower Facial Shape Questionnaire
Mar 10, 2025, 14:00 PM -
A European perspective on Health Resource Utilization (HRU) and Cost outcomes in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
Protocol for a Real-World Retrospective Study on Cardiovascular Outcomes in Japan Comparing Heated Tobacco Product Users, Cigarette Smokers, Former Smokers, and Never Smokers
Mar 10, 2025, 14:00 PM -
Validity and Accuracy of Asthma-Related ICD-10 Diagnosis Codes in United States Real-World Administrative Database
Mar 10, 2025, 14:00 PM -
Impact of Post-Discharge Rifaximin Use Following an Overt Hepatic Encephalopathy (OHE) Hospitalization on Annual Rates of OHE Rehospitalization in the United States
Mar 10, 2025, 14:00 PM -
Association of Chronic Conditions and Medication Burden with Patient Preferences for Long-Acting Antiretroviral Therapy in HIV Treatment
Mar 10, 2025, 14:00 PM -
A Targeted Literature Review of Value-Based Agreements (VBAs) for Cell and Gene Therapies in the United States
Mar 10, 2025, 14:00 PM -
Fostering the Identification and Dissemination ofHealth Technology Assessment Studies: The Brazilian HTA Database Case Study
Mar 10, 2025, 14:00 PM -
Economic Evaluation of NT-proBNP Testing to Facilitate Prevention of Heart Failure in Adults With Type 2 Diabetes
Mar 10, 2025, 14:00 PM -
Healthcare Cost and Resource Utilization among First Line (1L) Treated Patients with Metastatic Non-small Cell Lung Cancer (mNSCLC): Analysis of SEER-Medicare Linked Claims in the US
Mar 10, 2025, 14:00 PM -
Psychometric Analysis of the EORTC QLQ-NMIBC24 Using Data from a Global Phase 2 Randomized Trial of Erdafitinib[1] in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Mar 10, 2025, 14:00 PM -
Advancing Breast Cancer Research in Japan Using EHR-Derived Real-World Data
Mar 10, 2025, 14:00 PM -
Can We Move Beyond a Best Guess? The Feasibility of Transportability Analysis to Estimate the Effect of GLP-1 Inhibitors in the Canadian Population
Mar 10, 2025, 14:00 PM -
Costs of Type 2 Diabetes Mellitus and Obesity in Colombian Caribbean Poor Population: A Top-Down Approach from a Cardiovascular Risk Cohort, 2020-2022
Mar 10, 2025, 14:00 PM -
The Costs Associated with Healthcare Resource Use and Work Productivity for Care Partners of Multiple Myeloma Patients in the United States and Europe
Mar 10, 2025, 14:00 PM -
Trends in the Prescribing and Dispensing of GLP-1 Anti-Obesity Medications Among U.S. Adults with Cardiovascular Disease and Overweight or Obesity, 2021-2024
Mar 10, 2025, 14:00 PM -
Content Validation of the NEI-VFQ-25 With Patients With Subfoveal and Non-subfoveal Geographic Atrophy: A Qualitative Study
Mar 10, 2025, 14:00 PM -
Real-World Evaluation of Trastuzumab Deruxtecan Administration, Compliance, and Dose Utilization in Chinese Patients With HER2-Positive Advanced Breast Cancer
Mar 10, 2025, 14:00 PM
